flow trial semaglutide kidney outcomes nejm 2024 hazard ratio Semaglutides Are Poised to Remake Chronic Kidney Disease Care Effects of Semaglutide on Chronic

First bites The morning scramble meant that I was almost always stopping for some coffee and breakfast at Starbucks, McDonald's or Dunkin' Donuts, or hitting the hospital cafeteria

doi: 10.1002/jnr.22565 74 PellecchiaMTPivonelloRLongoKManfrediMTessitoreAAmboniMet al

A better understanding of dose-response relationships is needed to optimize therapy

Fair use statement The data and findings presented in this article are available for noncommercial use

Key advancements in peptide technology for triple receptor agonism: Application of computational modeling to peptide-receptor binding Fatty acid substitution for extended stability and duration -helical design for superior receptor fit Structure-based design to hone drug action and safety Engineering peptides that simultaneously bind and stimulate multiple receptors Clinical Implications With retatrutide, a triple receptor agonist that has been studied in clinical trials for obesity and metabolic diseases, including type 2 diabetes and MASLD